Patents by Inventor Richard Neubig

Richard Neubig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS
    Publication number: 20230159961
    Abstract: The disclosure relates to compounds of the formulae (I)-(IV) and their use as substrates for making terpenoids. New substrates for terpene biosynthesis and methods for making new types of terpenes are described herein. Diterpenes occupy a unique molecular space with critical pharmaceutical applications over a diverse spectrum including anti-microbial, anti-cancer, immunomodulatory and psychoactive properties.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 25, 2023
    Inventors: Edmund Ellsworth, Matthew Giletto, Björn Hamberger, Garret Miller, Richard Neubig
  • Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same
    Patent number: 10851072
    Abstract: Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: December 1, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Scott D. Larsen, Richard Neubig, Kim Hutchings, Dylan Kahl, Erika Mathes Lisabeth
  • Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same
    Patent number: 10662183
    Abstract: Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor (“MRTF/SRF”), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 26, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Scott D. Larsen, Richard Neubig, Andrew Haak, Kim Hutchings, Walajapet Rajeswaran, Dinesh Khanna, Erika Mathes Lisabeth
  • INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME
    Publication number: 20190308947
    Abstract: Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Application
    Filed: April 5, 2019
    Publication date: October 10, 2019
    Inventors: Scott D. Larsen, Richard Neubig, Kim Hutchings, Dylan Kahl, Erika Mathes Lisabeth
  • INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME
    Publication number: 20160145251
    Abstract: Disclosed herein are inhibitors of gene transcription mediated by myocardin-related transcription factor and serum response factor, or both myocardin-related transcription factor and serum response factor (“MRTF/SRF”), and methods for their use in treating or preventing cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts thereof: wherein the substituents are as described.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 26, 2016
    Inventors: Scott D. Larsen, Richard Neubig, Andrew Haak, Kim Hutchings, Walajapet Rajeswaran
  • METHODS AND COMPOSITIONS FOR INHIBITING RHO/MRTF-MEDIATED DISEASES AND CONDITIONS
    Publication number: 20150250769
    Abstract: The present disclosure relates to methods, compositions, and kits for the inhibition of signaling by members of the Rho GTPase family. Specifically, the disclosure relates to methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signaling and action of the transcription co-factors MRTF-A and/or MRTF-B. The disclosure finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis and fibrosis), Rho-mediated biological conditions, and in cell signaling research.
    Type: Application
    Filed: March 9, 2015
    Publication date: September 10, 2015
    Inventors: Scott D. Larsen, Jessica L. Bell, Richard Neubig, Kim Hutchings
  • Small molecule inhibitors of RGS proteins
    Patent number: 8865750
    Abstract: The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 21, 2014
    Assignees: The Regents of The University of Michigan, The University of Bath
    Inventors: Richard Neubig, Levi Blazer, Stephen Husbands, Scott Larsen, John Traynor
  • SMALL MOLECULE INHIBITORS OF RGS PROTEINS
    Publication number: 20120277273
    Abstract: The invention relates to compositions having RGS (regulator of G-protein Signaling) inhibiting activity, and methods of use thereof. In some embodiments, RGS-inhibiting compositions find use in research on or treatment of disease states (e.g., diabetes, epilepsy, neuropathic pain, depression and other diseases).
    Type: Application
    Filed: April 27, 2012
    Publication date: November 1, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Richard Neubig, Levi Blazer, Stephen Husbands, Scott Larsen, John Traynor
  • METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION
    Publication number: 20120252792
    Abstract: The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.
    Type: Application
    Filed: September 17, 2010
    Publication date: October 4, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Richard Neubig, Chris Evelyn, Jenny Ryu, Scott Larsen, Jessica Bell
  • Methods and Compositions for Modulating RHO-Mediated Gene Transcription
    Publication number: 20090264533
    Abstract: The present invention is directed to methods and compositions methods and compositions for determining and inhibiting gene transcription in mammalian cells. The invention relates to novel inhibitors of rho-mediated gene transcription and to compounds that may be used as therapeutic agents.
    Type: Application
    Filed: March 21, 2006
    Publication date: October 22, 2009
    Inventors: Richard Neubig, Chris Evelyn
  • Bead-based detection of ligand-GPCR-G protein complexes
    Patent number: 7189519
    Abstract: The present invention provides a general approach for G protein coupled receptors that may be used to define agonists and antagonists, and the specificity of receptor coupling to G protein subunits. Methods of the present invention use small volumes (microliters) and are compatible with high throughput flow cytometry. When assays of the present invention are multiplexed, the specificity of the interactions of a receptor with many G proteins may be determined simultaneously.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: March 13, 2007
    Assignees: STC.UNM, Univeristy of Michigan
    Inventors: Larry A. Sklar, Tione Buranda, Daniel Cimino, Alex T. Key, Richard Neubig, Peter C. Simons, Eric R. Prossnitz, Mei Shi
  • Bead-based detection of ligand-GPCR-G protein complexes
    Publication number: 20030235863
    Abstract: The present invention provides a general approach for G protein coupled receptors that may be used to define agonists and antagonists, and the specificity of receptor coupling to G protein subunits. Methods of the present invention use small volumes (microliters) and are compatible with high throughput flow cytometry. When assays of the present invention are multiplexed, the specificity of the interactions of a receptor with many G proteins may be determined simultaneously.
    Type: Application
    Filed: May 5, 2003
    Publication date: December 25, 2003
    Inventors: Larry A. Sklar, Tione Buranda, Daniel Cimino, T. Alex Key, Richard Neubig, Peter C. Simons, Eric R. Prossnitz, Mei Shi
  • Iodinated clonidine derivatives as radioactive imaging tracers
    Patent number: 4883649
    Abstract: Iodinated clonidine derivatives useful, inter alia, as a probe for identification and characterization of .alpha..sub.2 -adrenergic receptor sites and as tracers for imaging techniques such as positron emission tomography or computer assisted tomography. Binding competition studies have indicated that p-iodoclonidine, for example, is a particularly efficacious binder for .alpha..sub.2 -adrenergic sites.
    Type: Grant
    Filed: October 13, 1988
    Date of Patent: November 28, 1989
    Assignee: The University of Michigan
    Inventors: Raymond E. Counsell, Marcian Van Dort, Richard Neubig